clinical trial · NCT05761028
A Study of CM310 in Subjects With Moderate to Severe Asthma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·phase3·recruiting·n = 600
Moderate to Severe AsthmaCM310Placebo
brief summary
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week randomized treatment period, and a 4-week safety follow-up period.
started
Apr 28, 2023
primary completion
May 1, 2032
completion
May 1, 2032
last updated
Dec 15, 2023
official title
A Randomized, Double-Blind, Placebo-Controlled Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Subjects With Moderate to Severe Asthma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol